» Articles » PMID: 20796218

Omega-3 Fatty Acids in Critical Illness

Overview
Journal Nutr Rev
Date 2010 Aug 28
PMID 20796218
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Supplementation of enteral nutritional formulas and parenteral nutrition lipid emulsions with omega-3 fatty acids is a recent area of research in patients with critical illness. It is hypothesized that omega-3 fatty acids may help reduce inflammation in critically ill patients, particularly those with sepsis and acute lung injury. The objective of this article is to review the data on supplementing omega-3 fatty acids during critical illness; enteral and parenteral supplemental nutrition are reviewed separately. The results of the research available to date are contradictory for both enteral and parenteral omega-3 fatty acid administration. Supplementation with omega-3 fatty acids may influence the acute inflammatory response in critically ill patients, but more research is needed before definitive recommendations about the routine use of omega-3 fatty acids in caring for critically ill patients can be made.

Citing Articles

Docosahexaenoic acid alleviates LPS-induced cytotoxicity in HL-1 cardiac cells via improving stress-induced mitochondrial fragmentation.

Wang C, Han D, Feng X, Hu L, Wu J Heliyon. 2023; 9(12):e22465.

PMID: 38107281 PMC: 10724566. DOI: 10.1016/j.heliyon.2023.e22465.


Omega-3 Adjunctive Therapy in Idiopathic SSNHL: A Randomised, Triple-Blind, Placebo-Controlled Trial.

Rahmaty B, Aghazadeh K, Dabiri S, Zarandy M, Kouhi A, Yazdani N Iran J Otorhinolaryngol. 2023; 35(131):311-319.

PMID: 38074481 PMC: 10701245. DOI: 10.22038/IJORL.2023.71955.3444.


Calcium-Sensitive Receptors Alters Intestinal Microbiota Metabolites Especially SCFAs and Ameliorates Intestinal Barrier Damage in Neonatal Rat Endotoxemia.

Sun Y, Song J, Lan X, Ma F, Jiang M, Jiang C Infect Drug Resist. 2023; 16:5707-5717.

PMID: 37667808 PMC: 10475303. DOI: 10.2147/IDR.S420689.


Omega-3 fatty acid supplementation is associated with favorable outcomes in patients with sepsis: an updated meta-analysis.

Wang C, Han D, Feng X, Wu J J Int Med Res. 2020; 48(12):300060520953684.

PMID: 33373266 PMC: 7783898. DOI: 10.1177/0300060520953684.


Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?.

Darwesh A, Bassiouni W, Sosnowski D, Seubert J Pharmacol Ther. 2020; 219:107703.

PMID: 33031856 PMC: 7534795. DOI: 10.1016/j.pharmthera.2020.107703.


References
1.
Calder P . Immunonutrition in surgical and critically ill patients. Br J Nutr. 2007; 98 Suppl 1:S133-9. DOI: 10.1017/S0007114507832909. View

2.
Mayer K, Fegbeutel C, Hattar K, Sibelius U, Kramer H, Heuer K . Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003; 29(9):1472-81. PMC: 7187949. DOI: 10.1007/s00134-003-1900-2. View

3.
Battistella F, Widergren J, Anderson J, Siepler J, Weber J, MACCOLL K . A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J Trauma. 1997; 43(1):52-8; discussion 58-60. DOI: 10.1097/00005373-199707000-00013. View

4.
Petrak R, Balk R, Bone R . Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin. 1989; 5(2):303-14. View

5.
Rubenfeld G, Caldwell E, Peabody E, Weaver J, Martin D, Neff M . Incidence and outcomes of acute lung injury. N Engl J Med. 2005; 353(16):1685-93. DOI: 10.1056/NEJMoa050333. View